Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
01167 加科思藥業集團
Jacobio Pharmaceuticals Group
Listing Date2020/12/21
Listing Price14.000
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    50 lot
  • One Lot Success Rate

Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies. It is an explorer in developing clinical-stage small-molecule drug candidates to modulate enzymes by binding to their allosteric sites, i.e., sites other than the active site that catalyzes the chemical reaction, in order to address targets which are lack of easy-to-drug pockets where drugs can bind, such as protein tyrosine phosphatases (PTPs) and Kirsten rat sarcoma 2 viral oncogene homolog (KRAS).

The Group intends to proactively explore and enter into strategic and synergistic partnerships with leading multinational corporations (MNCs), as exemplified by the collaboration with AbbVie for its innovative, allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors. Such partnerships pool complementary expertise and resources to increase the chances of success for its drug candidates.

The Group owned one granted patent in China, one granted patent in Australia, three granted patents in Taiwan (China), one granted patent in Japan, and 63 pending patent applications.

With respect to its Core Product, JAB-3068, the Group owned one granted patent in Australia, one granted patent in Taiwan (China), one granted patent in Japan and 18 patent applications. The key patent applications of JAB-3068 were still pending in major markets including China and the U.S.

To prepare for late-stage clinical development of SHP2 inhibitors, the Group cooperates with a third party to construct new with a total gross floor area of around 20,000 sq.m. in Beijing, China. The commercial-scale manufacturing facilities are currently under construction. It is estimated that the construction and fit-out of the manufacturing facilities will be completed by the end of 2023.

MarketHong Kong (Main Board)
Business NatureHealth Care
Board Lot300
Registrar & Transfer OfficeComputershare Hong Kong Investor Services
No. of Offer Shares96.48m shares
No. of International Offer Shares86.83m shares
No. of HK Offer Shares9.65m shares
Offer Price$12.00 - $14.00
Nominal ValueUS$ 0.0001 each
Stock Code1167
Joint SponsorsGoldman Sachs (Asia), China International Capital Corporation Hong Kong Securities
Joint Global CoordinatorsGoldman Sachs (Asia), China International Capital Corporation Hong Kong Securities
Joint Bookrunners and Joint Lead ManagersGoldman Sachs (Asia), China International Capital Corporation Hong Kong Securities
Application PeriodDec 9 (Wed) - Noon, Dec 14 (Mon)
Price Determination DateOn or Before 5pm, Dec 14 (Mon)
Result Announcement DateOn or Before Dec 18 (Fri)
Dispatch of Shares and Refund ChequesOn or Before Dec 18 (Fri)
Dealings in Shares commence onDec 21, 2020. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
ExecutiveWang Yinxiang (Chairman), Wang Xiaojie, Hu Shaojing
Non-ExecutiveFeng Ting, Tang Yanmin, Lyu Dong, Chen Te-li
Independent Non-ExecutiveSong Ruilin , Wu Ge , Cai Daqing,Wu Xiaoming
Director Yinxiang Wang36.48%
Center Laboratories15.64%
Yi Shi6.75%
Hillhouse Capital Management7.49%
Qiming Venture Partners10.77%
(Year ended Dec 31)
2020 *20192018
Operating Profit(78,937)(194,170)(101,433)
Pre-Taxed Profit(810,904)(425,817)(155,935)
Attributable Profit for the period(810,896)(424,811)(149,212)
* For the six months ended June 30, 2020.
Offer Price$12.00 - $14.00
Capitalization$9,116m - $10,635m
Unaudited pro forma adj NAV / share$2.20 - $2.47
Assuming the offer price being at the mid-point of $13.00, the net proceeds raised would be HK$1,170.5m, of which:
* $1030.1m (88.0%) to be used primarily for the clinical development and commercialization of the following products ;
* $93.6m (8.0%) to be used for construction of its in-house GMP-compliant manufacturing facility; and
* the balance of $46.8m (4.0%) as additional working capital.
Code Name Nominal Change %Change
01801INNOVENT BIOdown67.400-0.800-1.173%
01877JUNSHI BIOdown44.550-0.450-1.000%
01952EVEREST MED-Bdown33.400-0.600-1.765%
02142HBM HOLDINGS-Bdown8.800-0.390-4.244%
02552HUA MEDICINE-Bup4.1200.0902.233%
02616CSTONE PHARMA-Bdown9.870-0.290-2.854%
03681SINOMAB BIO-Bunchange2.9000.0000.000%
15-min delayed, last updated: 02/12/2021 17:59
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.